Abstract
Aim: To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). Patients & methods: We enrolled 396 breast cancer patients, and TEC-ILI-associated factors were screened by logistic regression analyses. Results:SOD2 rs4880 and ABCG2 rs2231142 polymorphisms correlated with an increased risk of TEC-ILI. Multivariate analysis incorporating clinical and genetic factors revealed that ABCC1 rs246221 (CC) and SOD2 rs4880 (AG/GG) increased the risk of TEC-ILI. Patients with at least two risk factors among nonalcoholic fatty liver disease, high low-density lipoproteinemia levels and the rs246221 or rs4880 adverse genotypes exhibited a significantly increased risk of developing TEC-ILI. Conclusion: The combination of clinical and genetic risk factors had higher predictive value for TEC-ILI than the interclinical risk factors alone.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/pgs-2020-0080
Author contributions
S Huang, J Yang, F Fu, C Wang and M Liu designed the research. S Huang, X Guo, D Xiao, H Cai and M Liu performed the research. S Huang, J Yang, F Fu and B He analyzed the data. S Huang, J Yang and M Liu wrote the article. All authors approved the final version.
Acknowledgments
The authors would like to thank all the study participants who provided blood samples for this analysis.
Financial & competing interests disclosure
This work has been supported by the Startup Fund for Scientific Research, Fujian Medical University (no. 2017XQ1025); Joint Funds for the Innovation of Science and Technology, Fujian Province (no. 2018Y9045); Key Project for Youth Academic Talents from Health and Family Planning Commission of Fujian Province (no. 2019-ZQN-39); and the Fujian Provincial Department of Science & Technology of the People’s Republic of China (no. 2017Y0035). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The study was approved by the Institutional Review Board of Fujian Medical University Union Hospital (Fuzhou, China) (no. 2018KY053) and was in compliance with the Declaration of Helsinki. Written, informed consent was obtained from all the individuals that participated in the study.